February 2013 Volume 9, Issue 2
Volume 9, Issue 2 | February 2013
February 2013
In this Issue
Tools & Technology
Market share for Bio-Rad; focused direction for MorphoSys
Bio-Rad acquires MorphoSys’ AbD Serotec for approximately $70 million in a cash deal124 and counting
Venerable WHEATON Industries acquires chromatography vial supply company MicroLiter Analytical SuppliesShifting from manual to automatic
Roche, PSS unite to develop fully automated emulsion PCR instrumentAlliance of a lifetime
Almac and TTP Labtech partner on fluorescence lifetime technology for screening applicationsResearch & Development
End of the road for hESC opponents
U.S. Supreme Court declines to hear case seeking to restrict federal funding for human embryonic stem cell researchSutro-Celgene partnership a strategic fit
Companies collaborate on ADCs in $500 million-plus dealA LEAP forward for stem cell research
Collaboration will give world-class scientific team access to cutting-edge private technologiesStem cell developers Give Cures
CET, John Paul II Medical Research Institute to develop stem cell biobank for academia, government, industryNeuroscience focus of AstraZeneca, Vanderbilt deal
Vanderbilt University has joined forces with AstraZeneca PLC in a research deal to identify potential treatments for psychosis and other psychiatric symptoms associated with diseases such as Alzheimer’s and schizophreniaGlobal News
Getting under our skin
Pfizer, Halozyme partner on subcutaneous biologics delivery in potential $500 million-plus dealImproving immune response
German pharma Phenex joins forces with Janssen Biotech to target autoimmune, chronic inflammatory disordersTrio tackles translational research
Three-way collaboration tackles Parkinson’s diseaseGetting AMP-ed up
Daiichi Sankyo, Amplimmune partner to develop immune modulation therapyAligned in oncology
Chugai and Debiopharm announce an exclusive license agreement for anti-cancer agent FF284Diagnostics
Looking for a prenatal payoff
Illumina agrees to acquire Verinata Health for $350 million upfront plus $100 million in potential milestonesLilly, Dako make powerful companions
Collaboration on companion diagnostics will help speed oncology products to marketCDx deal is thrice as nice
Already partnered on the development of a companion diagnostic test for lymphoma, Eisai and Epizyme bring Roche Molecular Diagnostics into the foldQIAGEN plus four
Company’s agreements with four companies boost its diagnostic pipeline for personalized healthcare applicationsPassing the transplantation diagnostics torch
Immucor acquires LIFECODES business from Hologic Inc.Life Tech, Boston Children’s Hospital launch clinical genomics company
Life Technologies Corp. and Boston Children’s Hospital announced in early January the launch of Claritas Genomics, a new company formed to develop next-generation, genetic and genomics-based diagnostic testing solutionsContract Services
Controlling the flow of information
PAREXEL acquires regulatory information management provider LiquentA deal with 'significant efficiencies'
CNS acquires business assets of long-time partner BELTASSecond time around
LGC acquires bioanalytical sciences business from Quotient BioresearchNot your usual CRO arrangement
U.S.-based biopharma Onconova partners with Indian CRO GVK Biosciences on development of cancer drugsQuestcor Pharmaceuticals acquires BioVectra
Questcor Pharmaceuticals Inc. has signed a definitive agreement to acquire all issued and outstanding shares of BioVectra Inc., for an upfront payment of nearly $50 millionOmics & Systems Biology
Shire acquires Lotus Tissue Repair, gains potential therapy for rare skin disease
Acquisition consists of an undisclosed upfront payment as well as certain additional payments if specified safety and development milestones are metMy antisense is tingling
Strategic alliance between AstraZeneca and Isis aims to develop next-generation RNA therapeuticsFrom platform to clinic
Partnership between Heptares Therapeutics and Cubist Pharmaceuticals targets GCPRs for unmet needs in acute careAutism spectrum under study
Population Dx, Toronto’s Hospital for Sick Children discover gene variants for autism spectrum disorderMD Anderson, Trovagene to study transrenal BRAF mutations in primary, metastatic cancers
The University of Texas MD Anderson Cancer Center and Trovagene Inc., a developer of transrenal molecular diagnostics, have entered into a clinical collaboration with to detect transrenal BRAF mutations in the urine of patients with advanced or metastatic cancersFeature
SOT 2013 Annual Meeting and ToxExpo: One-stop toxicology shop (Part 1)
Annual meeting of the Society of Toxicology promises a wide range of toxicology and safety assessment scienceSOT 2013 Annual Meeting and ToxExpo: One-stop toxicology shop (Part 2)
Annual meeting of the Society of Toxicology promises a wide range of toxicology and safety assessment scienceCommentary
The times, they are a changin’ in the biopharma market
The biopharmaceutical development community has successfully developed a broad range of highly effective therapies for a wide variety of serious and debilitating diseases. However, developing biopharmaceuticals is inherently an extremely challenging and commercially risky undertaking, often working to tight timelines and typically resource- constrained.That’s not fair! Or is it?
Fair deserves a rest. A more precise set of words could include meritorious, disciplined and ethical.Editor's Focus
Sherley v. Sebelius: Where do we go from here?
“What we have going on right now with hESC research is the civil rights movement of the 21st century, a debate on whether science is going to enslave and manipulate the embryo,” says Samuel Casey, managing director and general counsel for the Law of Life Project, the law firm that represented the plaintiffs in Sherley v. Sebelius. “They are the new slaves. They are too small to vote. We are reopening the door on human subject experimentation, something that until now, only World War II closed the door on. I have spent the last 10 years trying to point out the truth, and this is where we today.”
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Discovering deeper insights into malaria research
Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Accelerating RNA therapeutic testing with liver microphysiological platforms
Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
Shining light on the subcellular proteome
Discover how innovative proteomics tools help researchers peer into once inaccessible organelles, allowing for new targets for drug discovery and development.
